MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-024-02242-6

Медицинская библиотека · Leukemia · 2024

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.

Wang Trent P, Ahn Kwang W, Shadman Mazyar, Kaur Manmeet, Ahmed Nausheen, Bacher Ulrike, Cerny Jan, Chen Andy, Epperla Narendranath, Frigault Matthew, Grover Natalie, Haverkos Bradley, Hill Brian, Hossain Nasheed, Iqbal Madiha, Jain Tania, Krem Maxwell M, Maakaron Joseph, Modi Dipenkumar, Alhaj Moustafa Muhamad, Riedell Peter, Savani Bipin, Sica R Alejandro, Sureda Anna, Wudhikarn Kitsada, Herrera Alex F, Sauter Craig, Hamadani Mehdi, Jimenez Jimenez Antonio

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2-9). At two years post-infusion, the probability of progression-free survival was 43.5% (95% CI 34.4-52.8) and the probability of overall survival was 63.8% (95% CI 54.4-72.6). The cumulative incidence rates of non-relapse mortality and relapse/progression at two years were 9.2% (95% CI 4.5-15.4) and 47.3% (95% CI 38.2-56.6), respectively. The rate of grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were 2.2% and 8.2%, respectively. In summary, CAR-T in heavily pretreated patients with LBCL who are in CR following two or more lines of prior therapy demonstrate that a subset of patients may remain free of progression at two years. Additionally, the toxicity profile was impressive with very low rates of grade 3 CRS and ICANS.

Для цитирования: Wang Trent P, Ahn Kwang W, Shadman Mazyar, Kaur Manmeet, Ahmed Nausheen, Bacher Ulrike, Cerny Jan, Chen Andy, Epperla Narendranath, Frigault Matthew, Grover Natalie, Haverkos Bradley, Hill Brian, Hossain Nasheed, Iqbal Madiha, Jain Tania, Krem Maxwell M, Maakaron Joseph, Modi Dipenkumar, Alhaj Moustafa Muhamad, Riedell Peter, Savani Bipin, Sica R Alejandro, Sureda Anna, Wudhikarn Kitsada, Herrera Alex F, Sauter Craig, Hamadani Mehdi, Jimenez Jimenez Antonio. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.. Leukemia. 2024. DOI: 10.1038/s41375-024-02242-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.